Your First Patent Application Filing

For most life sciences startups, the patent filing journey begins in their home country. In the United States, this means filing with the United States Patent and Trademark Office (USPTO); in Europe, with a national patent office or the European Patent Office (EPO); and so on. Filing domestically can be a common approach for practical reasons — it is generally the least expensive initial step, it is conducted in the applicant’s own language and legal system, and it establishes what is known as a priority date. That priority date is a critically important concept: it marks the moment from which your invention is legally considered to have been disclosed, and it determines who wins in the event that two inventors file applications for the same invention around the same time. In nearly all jurisdictions, the first party to file wins that race, making the act of filing promptly, even before a product may be fully developed, a strategically significant decision.

The Role of the Provisional Application

Startups have access to a particularly useful tool called a provisional patent application. A provisional is a relatively informal and lower-cost filing that does not itself result in a granted patent, but which immediately secures a priority date and gives the applicant twelve months to file a full, formal application. During that twelve-month window, the company can continue refining its technology, test the commercial landscape, seek investment, and disclose the invention publicly — all while the priority date is held in reserve. For a cash-constrained early-stage startup, this breathing room can be invaluable. It allows founders to validate their technology and business model before committing to the considerably greater expense of a full patent prosecution process. Most other countries have similar mechanisms, though the rules may vary, and it is important to work with a qualified patent attorney to ensure a provisional filing is drafted with sufficient detail to provide meaningful protection.

Going International: The PCT System

Once a startup has established a priority date, the question quickly becomes how and where to seek protection internationally. Life sciences companies almost always need to think beyond their domestic market — a drug, device, or diagnostic that cannot be protected in major commercial territories like Europe, Japan, China, or South Korea may be vulnerable to competition in the markets that matter most. The most common route for managing international filings is the Patent Cooperation Treaty, universally known as the PCT. A PCT application, filed through the World Intellectual Property Organization (WIPO), allows a startup to file a single international application that effectively reserves the right to pursue patents in over 150 member countries simultaneously. Critically, it delays the need to commit to specific national filings — and the significant costs associated with them — for up to 30 months from the original priority date. This gives a startup additional time to secure funding, refine its commercial strategy, and make more informed decisions about which markets to prioritize.

Making Strategic Choices About Where to File

The PCT system is a powerful tool, but it does not eliminate the need for careful strategic thinking about where to ultimately seek patent protection. Filing and maintaining patents in multiple countries is expensive, and for a startup with limited resources, choices have to be made. The right answer will depend on several factors specific to each company: where the largest markets for the product are located, where competitors or potential licensees are based, where manufacturing is likely to occur, and which jurisdictions potential investors or acquirers are likely to care about. In life sciences, the United States, Europe, Japan, China, and South Korea are typically considered the core filing territories for most products, though the right set of countries will vary by technology area and business model. These are decisions best made in close consultation with a patent attorney who understands both the legal landscape and the company’s commercial strategy — because a patent filing strategy that is not aligned with the business plan is unlikely to create the value that makes IP so important in the first place.

This article is part of our Life Sciences Startup IP Resource Center.